MX2018001499A - Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos. - Google Patents

Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.

Info

Publication number
MX2018001499A
MX2018001499A MX2018001499A MX2018001499A MX2018001499A MX 2018001499 A MX2018001499 A MX 2018001499A MX 2018001499 A MX2018001499 A MX 2018001499A MX 2018001499 A MX2018001499 A MX 2018001499A MX 2018001499 A MX2018001499 A MX 2018001499A
Authority
MX
Mexico
Prior art keywords
liquid polymer
drugs
delivery system
polymer delivery
extended administration
Prior art date
Application number
MX2018001499A
Other languages
English (en)
Inventor
Milton Downing John
Saxena Vipin
Middleton John
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of MX2018001499A publication Critical patent/MX2018001499A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Las composiciones farmacéuticas de polímero líquido con un poliéster líquido biodegradable que tiene un grupo terminal ácido carboxílico, un solvente biocompatible, y un agente farmacéutico activo, son útiles para ser administrados en el cuerpo para proveer una liberación prolongada ampliada del fármaco.
MX2018001499A 2015-08-03 2016-08-03 Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos. MX2018001499A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200198P 2015-08-03 2015-08-03
US201662275407P 2016-01-06 2016-01-06
PCT/US2016/045334 WO2017024027A1 (en) 2015-08-03 2016-08-03 Liquid polymer delivery system for extended administration of drugs

Publications (1)

Publication Number Publication Date
MX2018001499A true MX2018001499A (es) 2018-08-01

Family

ID=56684769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001499A MX2018001499A (es) 2015-08-03 2016-08-03 Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.

Country Status (20)

Country Link
US (3) US10786515B2 (es)
EP (2) EP3331495B1 (es)
JP (1) JP6949820B2 (es)
KR (1) KR20180030413A (es)
CN (1) CN107920988B (es)
AU (1) AU2016302252B2 (es)
BR (1) BR112018002414B1 (es)
CA (1) CA2994704A1 (es)
DK (1) DK3331495T3 (es)
EA (1) EA036951B1 (es)
ES (1) ES2836805T3 (es)
HK (1) HK1255638A1 (es)
HR (1) HRP20201991T1 (es)
HU (1) HUE052832T2 (es)
IL (1) IL257221B (es)
MX (1) MX2018001499A (es)
PT (1) PT3331495T (es)
TW (1) TWI718168B (es)
WO (1) WO2017024027A1 (es)
ZA (1) ZA201800591B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400363B (zh) 2006-01-18 2012-08-29 昌达生物科技公司 具有增强的稳定性的药物组合物
EP3331495B1 (en) * 2015-08-03 2020-11-04 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
UY38386A (es) 2018-09-25 2020-04-30 Tolmar Int Ltd Sistema de suministro de polímero líquido para la administración prolongada de fármacos
CN109966557A (zh) * 2018-12-05 2019-07-05 博志生物科技有限公司 局部缓释Abaloparatide或相关多肽的GelMA水凝胶的制备方法及应用
JP2022551818A (ja) 2019-09-30 2022-12-14 トルマー インターナショナル リミテッド 活性医薬成分としてのペプチドの延長送達のための液体ポリマー組成物およびシステム
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
US20230355511A1 (en) 2020-09-30 2023-11-09 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6197320B1 (en) 1994-03-11 2001-03-06 Shalaby W. Shalaby Absorbable E-caprolactone polymers and medical devices
US5668288A (en) * 1996-04-16 1997-09-16 Depuy Orthopaedics, Inc. Polyester ionomers for implant fabrication
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2006065951A2 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
CN101400363B (zh) * 2006-01-18 2012-08-29 昌达生物科技公司 具有增强的稳定性的药物组合物
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US20100216948A1 (en) * 2009-01-23 2010-08-26 Tipton Arthur J Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
KR20130100345A (ko) * 2010-11-04 2013-09-10 신닛테츠 수미킨 가가쿠 가부시키가이샤 하드코트층 부착 폴리카보네이트
WO2013036309A2 (en) * 2011-06-10 2013-03-14 Wong Vernon G Sustained release formulations for delivery of proteins to the eye and methods of preparing same
JP5989126B2 (ja) * 2011-10-17 2016-09-07 ポリ−メド インコーポレイテッド 吸収性現場ゲル形成システム、その製造方法及びその使用
EP3331495B1 (en) 2015-08-03 2020-11-04 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs

Also Published As

Publication number Publication date
IL257221A (en) 2018-03-29
JP2018522906A (ja) 2018-08-16
EP3331495A1 (en) 2018-06-13
US10786515B2 (en) 2020-09-29
ZA201800591B (en) 2021-07-28
US20240066039A1 (en) 2024-02-29
AU2016302252B2 (en) 2022-01-20
CN107920988B (zh) 2021-08-17
TW201717960A (zh) 2017-06-01
US11779589B2 (en) 2023-10-10
EA036951B1 (ru) 2021-01-19
TWI718168B (zh) 2021-02-11
EP3804698B1 (en) 2024-01-31
US20180214459A1 (en) 2018-08-02
BR112018002414B1 (pt) 2023-11-21
PT3331495T (pt) 2020-12-07
BR112018002414A2 (pt) 2018-09-18
CN107920988A (zh) 2018-04-17
AU2016302252A1 (en) 2018-02-22
HK1255638A1 (zh) 2019-08-23
DK3331495T3 (da) 2020-12-14
IL257221B (en) 2022-01-01
EA201890436A1 (ru) 2018-09-28
HRP20201991T1 (hr) 2021-02-05
HUE052832T2 (hu) 2021-05-28
JP6949820B2 (ja) 2021-10-13
EP3331495B1 (en) 2020-11-04
EP3804698A1 (en) 2021-04-14
WO2017024027A1 (en) 2017-02-09
KR20180030413A (ko) 2018-03-22
ES2836805T3 (es) 2021-06-28
CA2994704A1 (en) 2017-02-09
US20210060036A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
MX2021001118A (es) Composiciones que comprenden fibras obtenidas electrohidrodinamicamente para la administracion de dosificaciones especificas de una sustancia activa a piel o mucosa.
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
WO2012035429A3 (en) Remotely controlled drug delivery systems
EA033537B1 (ru) Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
MX2019003804A (es) Dispositivos implantables para suministro de medicamento con liberacion de descarga reducida.
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP4233978A3 (en) Oral delivery of active drug substances
MX364396B (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
MX352907B (es) Composiciones de un poliortoéster y un solvente aprótico.
WO2015095624A3 (en) Drug mixing and delivery system and method
MD20160079A2 (ro) Sistem de livrare a medicamentului
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
AR116501A1 (es) Sistema de suministro de polímero líquido para administración extendida de drogas
CR20140358A (es) Sistema para la administración de fármacos
PE20160534A1 (es) Sistema de administracion intrauterina
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
MX2016001607A (es) Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas.
MX2016012319A (es) Formulaciones antihelminticas veterinarias estables.
MX2015007731A (es) Formulacion farmaceutica que comprende ciclesonida.
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
WO2016036823A3 (en) Self-assembling drug delivery vehicles with ionically cross-linked drugs
EP3664856A4 (en) POLY (ESTER-UREA) FOR MEMORY AND DRUG ADMINISTRATION
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
AR110595A1 (es) Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos